尿路上皮癌的组织学亚型与分化:病理、基因组学及治疗意义
本文综述膀胱癌组织学亚型与分化的病理、分子特征及治疗结局。亚型常被低估分期且易淋巴结转移,支持早期根治性膀胱切除;小细胞癌受益于铂类/依托泊苷方案,而鳞状、浆细胞样、肉瘤样及微乳头状肿瘤对常规系统治疗反应不一。基因组分析提示可靶向改变但临床意义未明。
要点
- 组织学亚型常被低估分期且易淋巴结转移,支持早期根治性膀胱切除。
- 小细胞尿路上皮癌一致受益于铂类/依托泊苷方案。
- 鳞状、浆细胞样、肉瘤样及微乳头状肿瘤对常规系统治疗反应不一。
核心结论
- 组织学亚型与分化是高风险且生物学独特的疾病表型,可能不符合当前一刀切治疗模式。
研究设计与样本
- 叙述性综述,涵盖队列研究、临床试验和人群分析,评估膀胱癌亚型的形态学、免疫表型、基因组改变及治疗结局。
主要发现
- 组织学亚型常被低估分期且常见淋巴结转移,支持早期根治性膀胱切除甚至用于某些临床非肌层浸润性膀胱癌。
- 小细胞尿路上皮癌一致受益于铂类/依托泊苷方案;鳞状、浆细胞样、肉瘤样及微乳头状肿瘤对常规系统治疗反应率不一。
- 三联治疗对小细胞尿路上皮癌的局部控制可能接近根治性膀胱切除,但对鳞状和腺癌为主者似乎较差。
- 基因组分析提示可靶向改变但临床意义不明确;免疫检查点阻断和抗体药物偶联物在亚型膀胱癌中偶有活性。
临床怎么用
- 组织学亚型常被低估分期,应重视早期根治性膀胱切除的评估。
- 小细胞尿路上皮癌优先考虑铂类/依托泊苷方案。
- 非小细胞亚型对常规系统治疗反应不一,需个体化策略。
局限性
- 需更深入临床和转化分析及稳健充分把握度的队列以理解各亚型临床行为并定制最佳治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management. METHODS: We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes. KEY FINDINGS AND LIMITATIONS: Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non-muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current "one-size-fits-all" treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies.
引用
- Aydogdu C, Bukavina L, Cheng L, et al. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. 2026. PMID: 42362411. doi:10.1016/j.eururo.2026.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。